A phase Ib, proof of concept, randomized, double-blind, placebo-controlled, multicentre study to evaluate the safety, tolerability, pharmacokinetics and efficacy of AVR-560 in hepatitis C patients

Trial Profile

A phase Ib, proof of concept, randomized, double-blind, placebo-controlled, multicentre study to evaluate the safety, tolerability, pharmacokinetics and efficacy of AVR-560 in hepatitis C patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 May 2016

At a glance

  • Drugs AVR 560 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 17 May 2016 New trial record
    • 15 May 2014 According to an Alla Chem media release, the final results of this study will be presented in at a major scientific conference in the H2 of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top